Novo Nordisk A/S (NYSE:NVO) Stock Price Down 1.2% on Analyst Downgrade

Novo Nordisk A/S (NYSE:NVO)’s share price fell 1.2% during mid-day trading on Wednesday after Kepler Capital Markets downgraded the stock from a buy rating to a hold rating. The stock traded as low as $37.65 and last traded at $38.1270. 54,793,532 shares were traded during mid-day trading, an increase of 104% from the average session volume of 26,806,613 shares. The stock had previously closed at $38.59.

Several other equities analysts have also recently weighed in on NVO. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, Citigroup initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating for the company. Six research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $56.07.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Positive Phase‑2 China results for a triple‑agonist (UBT251) that produced ~20% body‑weight loss, bolstering Novo’s obesity pipeline and collaboration footprint in Greater China. Novo Nordisk’s China Obesity Drug Cuts Nearly One-Fifth Of Body Weight
• Positive Sentiment: Novo signed a strategic deal with Vivtex to develop next‑generation oral obesity/diabetes medicines (deal valued up to ~$2.1bn), which could extend market reach beyond injectables if the oral delivery works at scale. Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
• Neutral Sentiment: Short interest fell meaningfully in February (roughly a 15% drop), reducing one source of selling pressure and lowering the days‑to‑cover — a technical datapoint worth monitoring for volatility changes.
• Negative Sentiment: Multiple analyst downgrades and coverage cuts have pressured the stock, with recent notes and headlines pointing to reduced ratings and target cuts amid pipeline and competitive concerns. Novo Nordisk A/S (NYSE:NVO) Stock Rating Lowered by Kepler Capital Markets
• Negative Sentiment: Shareholder litigation inquiries and class‑action investigations have been announced (Pomerantz, Schall Law Firm), creating legal overhang and potential costs/distraction for management. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Pricing pressure and a reported halving of Wegovy prices have heightened margin and competitive concerns, feeding the narrative of a structural challenge in the obesity franchise. Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Revolve Wealth Partners LLC grew its position in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the last quarter. AQR Capital Management LLC increased its stake in Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares during the period. Sivia Capital Partners LLC lifted its holdings in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after buying an additional 1,587 shares in the last quarter. Focus Partners Advisor Solutions LLC boosted its position in Novo Nordisk A/S by 16.3% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 7,318 shares of the company’s stock valued at $504,000 after buying an additional 1,024 shares during the period. Finally, Nisa Investment Advisors LLC grew its stake in Novo Nordisk A/S by 33.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock worth $83,000 after acquiring an additional 300 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.4%

The stock’s 50-day moving average price is $52.96 and its 200 day moving average price is $52.93. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market capitalization of $167.97 billion, a PE ratio of 10.84 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.